<DOC>
	<DOCNO>NCT00936143</DOCNO>
	<brief_summary>This prospective open-label study evaluate efficacy safety infliximab ( Remicade ) treat patient early ankylose spondylitis ( AS ) . Infliximab inject intra-venous baseline , 2nd week , 6th week , 12th week 24th week , dose 5mg/kg . The major outcome index ASAS20 , minor outcome index include ASAS50 ASAS70 , BASDAI20 , BASDAI50 BASDAI70 . And MRI sacroiliac joint necessary . The adverse event time record .</brief_summary>
	<brief_title>Efficacy Safety Study Infliximab ( Remicade ) Treat Early Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . 16 65 year old , sign informed consent ; 2. fulfill ESSG criterion diagnosis SpA ; fulfill 1984 modified NewYork criterion AS ; 3. inflammatory back pain define Calin criterion ; 4. disease duration range 6 month 2 year ; 5 . BASDAI score 4 ; 6 . MRI score sacroiliac joint 4 ; 7. lab examination : hemoglobin 90 gram/liter . Aspartate aminotransferase Alanine aminotransferase le 2 fold upper level normal range . Creatine less upper level normal range . 1 . History psoriasis inflammatory bowel disease . 2 . Intraarticular injection cortisone within 3 month . 3 . Patients take cortisone , SASP MTX , unless dose stable least 3 month . 4 . Active iritis . 5 . History heart failure , multiple sclerosis , COPD , lymphoma tumor , tuberculosis . 6 . Female pregnancy breast feeding . 7 . History mental disease poor compliance . 8 . History drug abuse alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Spondylitis , Ankylosing</keyword>
	<keyword>infliximab</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>